CVS Health Corporation faces legal challenges over allegedly misleading claims about calcium and glucosamine supplements. The company is accused of misrepresenting the efficacy of glucosamine for joint health and mislabeling the dosages on both calcium and glucosamine products. The most prominent case, Kroessler et al. v.
CVS Health Corp., filed in federal court in February 2019, alleges that CVS falsely advertised glucosamine supplements as providing “joint flexibility, mobility, comfort, and strength” when scientific research does not support these claims. Additionally, CVS has been accused of misleading consumers about dosage amounts on its calcium and glucosamine supplement labels, which were reported in July 2026. These class actions raise important questions about supplement marketing and labeling accuracy. When consumers purchase supplements at major retailers like CVS, they typically assume the marketing claims are supported by evidence and that the dosage information on labels is accurate. The lawsuits challenge both assumptions, pointing to gaps between what CVS allegedly claimed and what independent scientific research has found.
Official resource:
- NIH GAIT Study: Glucosamine and Chondroitin for Osteoarthritis — Access the primary clinical evidence showing glucosamine plus chondroitin provided no overall benefit compared to placebo for joint pain.
Table of Contents
- What Is the Kroessler v. CVS Glucosamine Class Action?
- What Does the Scientific Evidence Say About Glucosamine?
- The CVS Calcium and Glucosamine Dosage Mislabeling Allegations
- What Are the Approved Health Claims for Calcium Versus What CVS Allegedly Claimed?
- What Does Research Show About Calcium Supplements and Fracture Prevention?
- Cardiovascular and Renal Risks Associated with Calcium Supplements
- Understanding Standard Dosages and Why They Matter in Class Actions
What Is the Kroessler v. CVS Glucosamine Class Action?
The Kroessler case (Kroessler et al. v. CVS Health Corp., No. 19-cv-277, filed in the Southern District of California in February 2019) is a federal class action alleging that CVS falsely advertised glucosamine supplements with claims about joint health. The complaint argues that CVS marketed glucosamine as improving “joint flexibility, mobility, comfort, and strength” when the company knew or should have known that scientific evidence does not support these claims.
This is not a niche legal dispute—glucosamine is one of the most popular over-the-counter supplements in the United States, and CVS is one of the largest retailers of such products. The case experienced a significant legal victory for consumers in October 2020, when the U.S. Court of Appeals for the Ninth Circuit reversed a lower court decision that had dismissed the case. The district court had initially ruled that federal dietary supplement regulations preempted state consumer protection laws, which would have ended the lawsuit before trial. The Ninth Circuit disagreed, finding that state consumer protection claims could proceed alongside federal dietary supplement law. The case was remanded for trial proceedings, meaning the claims about CVS’s glucosamine marketing remain alive and will be tested in court.
What Does the Scientific Evidence Say About Glucosamine?
The foundational scientific evidence on glucosamine comes from a major NIH-funded trial called the Glucosamine/Chondroitin Arthritis Intervention Trial (GAIT), published in the New England Journal of Medicine in February 2006. This was a large, rigorous study: a 6-month, double-blind, placebo-controlled, multicenter trial designed to test whether glucosamine plus chondroitin could reduce osteoarthritis symptoms. The key finding was sobering for supplement manufacturers: glucosamine plus chondroitin showed no statistically significant effect on osteoarthritis symptoms overall. This means the improvements seen in the supplement group were no better than what participants experienced when given a placebo.
There is one caveat worth noting: exploratory analyses suggested a possible benefit in a subgroup of participants who had moderate-to-severe knee pain, where the treatment showed approximately a 20% reduction in pain compared to the 60% overall placebo effect. However, exploratory subgroup analyses in clinical trials are considered lower-quality evidence and are often not validated in follow-up studies. The FDA has maintained since 2004 (and reaffirmed in 2012) that there is no credible scientific evidence to support health claims regarding glucosamine and chondroitin sulfate reducing osteoarthritis risk, joint degeneration, or cartilage deterioration. These supplements are classified as dietary supplements, not FDA-approved drugs, which means they face less rigorous approval requirements but also face restrictions on the health claims they can make.
The CVS Calcium and Glucosamine Dosage Mislabeling Allegations
In July 2026, Class Action U reported that CVS was facing a class action alleging misleading advertising about dosages on both calcium and glucosamine supplements. This allegation is distinct from (though related to) the question of efficacy; it concerns whether the dosage information presented on CVS supplement labels is accurate. Dosage labeling is a matter of compliance with federal and state regulations, and if CVS misrepresented dosages, consumers could have purchased products thinking they were getting a certain amount of the active ingredient when they were actually getting something different.
For glucosamine specifically, the most commonly studied and recommended dose is 1,500 mg daily. This dosage emerged from years of clinical research and is considered the standard reference point for glucosamine supplementation. Glucosamine comes in different chemical forms—glucosamine sulfate (a prescription-grade form) has shown superiority to glucosamine hydrochloride in some 3-year studies, and the 1,500 mg dose is generally well-tolerated at this level. If CVS products were labeled with dosages that did not match what was actually in the bottle, or if the label suggested a different serving size than what was listed in the supplement facts panel, consumers could have been misled about what they were purchasing.
What Are the Approved Health Claims for Calcium Versus What CVS Allegedly Claimed?
The FDA has authorized a specific health claim for calcium supplements: “Adequate calcium throughout life may reduce the risk of osteoporosis.” This is the framework within which calcium supplement manufacturers are legally permitted to market their products. The FDA has also recognized 10 different forms of calcium as safe for supplementation, including calcium carbonate, citrate, phosphate, chloride, lactate, sulfate, glycerophosphate, pyrophosphate, oxide, and pantothenate. The current FDA Daily Value for calcium is 1,300 mg for adults and children over 4 years old.
What CVS allegedly claimed (based on the july 2026 dosage mislabeling allegation) is not yet publicly detailed in full, but the class action framework suggests the company may have either made health claims beyond what the FDA allows, or mislabeled the amount of calcium in its products. The difference matters: marketing calcium for preventing osteoporosis is allowed; marketing it for preventing arthritis, heart disease, or other conditions beyond osteoporosis prevention is not. Similarly, claiming a product contains 1,000 mg of calcium when it actually contains 800 mg is a factual misrepresentation that violates consumer protection laws and federal supplement labeling requirements.
What Does Research Show About Calcium Supplements and Fracture Prevention?
The clinical evidence on calcium supplementation is more mixed than many consumers realize. A large body of trial evidence shows that calcium supplements do NOT prevent fractures in community-dwelling adults—people living in their own homes, as opposed to nursing home residents. The U.S. Preventive Services Task Force (USPSTF) found that daily doses of calcium below 1,000 mg plus vitamin D below 400 IU do not prevent fractures in postmenopausal women, with moderate certainty in this finding.
This is significant because many over-the-counter calcium supplements sold at CVS come in doses around 500–600 mg per serving, and many consumers do not take them daily or in combination with adequate vitamin D. There is one important exception to this pattern: calcium supplements do show meaningful benefit for institutionalized individuals or those with documented calcium deficiencies. For people living in nursing homes or assisted care facilities, calcium supplementation has been shown to help prevent fractures. Additionally, pregnant women represent a special case: calcium supplementation in pregnancy shows a 55% reduction in preeclampsia risk overall, and a 64% reduction in populations where baseline calcium intake was below 800 mg per day. These exceptions are important because they show that calcium supplements can be medically beneficial in specific populations, even if they don’t work as well for the general public.
Cardiovascular and Renal Risks Associated with Calcium Supplements
Beyond questions of efficacy, calcium supplements carry documented health risks that are often not highlighted in marketing materials. Calcium supplements commonly cause gastrointestinal side effects, including constipation, bloating, and nausea, which can lead consumers to stop taking them. More seriously, calcium supplementation increases the risk of renal calculi—kidney stones—a painful condition that can require medical intervention. Meta-analyses of randomized controlled trials suggest a 10–20% increased risk of myocardial infarction (heart attack) with calcium supplementation, a finding that has prompted questions about whether the cardiovascular benefits of osteoporosis prevention are offset by cardiac risks.
These risks are not theoretical or rare. They represent documented findings from large-scale analyses of clinical trial data. A consumer purchasing calcium supplements at CVS to prevent osteoporosis, based on the FDA-authorized claim, may not be aware that the supplement could increase their risk of kidney stones or heart problems, especially if they take it at high doses or over many years. The NIH Calcium Fact Sheet and recent research published in Springer Nature’s Current Osteoporosis Reports (2025) document these risks, suggesting that blanket calcium supplementation for community-dwelling adults is not as straightforwardly beneficial as marketing claims often suggest.
Understanding Standard Dosages and Why They Matter in Class Actions
When a class action alleges dosage mislabeling, it typically means one of three things: the label states a dosage that differs from what is actually in the product, the serving size is misrepresented, or the amount of active ingredient per serving does not match the label claim. For glucosamine, as noted earlier, the standard studied dose is 1,500 mg daily. If CVS products were labeled as containing 1,500 mg per serving when they actually contained 1,000 mg or 1,200 mg, that would constitute mislabeling. For calcium, the FDA Daily Value of 1,300 mg serves as a reference point; if a CVS label claimed to provide 1,000 mg of calcium but actually delivered 750 mg, that would also violate federal labeling regulations.
These details are not merely technical—they affect whether consumers received what they paid for. Dosage mislabeling can be intentional or the result of poor quality control in manufacturing. Either way, it undermines consumer trust and violates federal labeling requirements. A consumer who purchased what they believed was a glucosamine supplement meeting the 1,500 mg standard dose, or a calcium supplement providing the FDA Daily Value amount, may have actually been receiving a lower dose. Over weeks or months of supplementation, this shortfall could mean the consumer was not receiving the benefit they expected, and in the case of calcium, might not have been taking enough to meet their actual nutritional needs.
- —